Molecular subgroup of periodontitis revealed by integrated analysis of the microbiome and metabolome in a cross-sectional observational study

Hee Sam Na,a,b Suhkmann Kim,c Seonghye Kim,d Yeuni Yu,e Si Yeong Kim,a,b Hyun-Joo Kim,f Ju Youn Lee,f Jae-Hyung Lee and Jin Chung,a,b

*Department of Oral Microbiology, School of Dentistry, Pusan National University, Busan, South Korea; a Oral Genomics Research Center, Pusan National University, Busan, South Korea; b Department of Chemistry, Center for Proteome Biophysics, and Chemistry Institute for Functional Materials, Pusan National University, Busan, South Korea; c Interdisciplinary Program of Genomic Science, Pusan National University, Busan, South Korea; d Department of Periodontology, School of Dentistry, Pusan National University, Busan, South Korea; e Dental Research Institute, School of Dentistry, Pusan National University, Busan, South Korea; f Department of Oral Microbiology, School of Dentistry, Kyung Hee University, Seoul, South Korea; g Department of Life and Nanopharmaceutical Sciences, Kyung Hee University, Seoul, South Korea; h Kyung Hee Medical Science Research Institute, Kyung Hee University, Seoul, South Korea

ABSTRACT

Background: Periodontitis (PT) is a multifactorial, chronic inflammatory disease that can have heterogeneous clinical presentations. The oral microbiome and its metabolites have been implicated as the causes and regulators of PT pathogenesis. In this study, we assessed the oral microbiome and its metabolome in PT patients to clarify the interactions between the microbiome and its metabolites.

Methods: A total of 112 subjects were recruited. Buccal and supragingival samples were collected for microbiome analysis. Saliva samples were collected for metabolomic analyses. Microbiome and metabolome data were analyzed and further integrated for combined analysis using various bioinformatics approaches.

Results: Oral metabolomic analysis identified 28 metabolites distinguishing the healthy (H) and PT groups. PT group were further clustered into two subgroups (PT G1 and PT G2) depending on metabolite profiles. Oral microbiome analysis revealed discriminatory bacterial species in the H, PT G1, and PT G2 microbiota. Interestingly, PT G2 had significantly higher concentration of short chain fatty acids and higher abundance of pathogenic bacteria. Integrated analysis of the microbiome and metabolome showed close association.

Conclusion: Our results provide evidence of a close interplay between the oral microbiome and metabolome. Multi-omics approach including microbiome and microbe-associated metabolites may serve as diagnostic biomarkers and enhance treatment prediction in periodontal disease.

Introduction

Periodontitis (PT) is a multifactorial and chronic inflammatory disease that leads to the loss of periodontal attachment for the root surface and alveolar bone resorption. PT has heterogeneous clinical presentations, and its diagnosis is primarily based on clinical examination and radiographic parameters [1,2]. Gradually, the traditional culture-based, biochemical, and immunological assays for clinical diagnostics are being replaced by more advanced diagnostic tools [3,4]. Metagenomics focuses on the microbial communities that colonize areas of the human body, such as the oral cavity [5]. PT is initiated by the colonization of periodontal pathogens including Gram-negative Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia, which are frequently isolated from subgingival dental plaques in PT patients. These bacteria were initially considered specific pathogens of periodontal disease [6]. A strong correlation between oral bacteria and periodontal disease has been reported [7–11].

Oral microbes are capable of converting the complex chemicals present in saliva into a milieu of metabolites [12]. Recent studies suggest that microbial metabolites are important in connecting the oral microbiota to PT [13,14]. Thus, disruption of the microbiome and the balance of metabolites can induce an excessive inflammatory response resulting in tissue destruction in PT. However, the interplay between the oral microbiota and metabolites as well as their roles in PT development have not been effectively addressed.

CONTACT Jin Chung chung@pusan.ac.kr Department of Oral Microbiology, School of Dentistry, Pusan National University, Busandaehak-ro 49, Mulgeum-eup, Yangsan, Gyeongsangnam-do 50612, Republic of Korea

* These authors contributed equally to this work.

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Materials and methods

Study population and clinical examination

A total of 112 subjects was recruited in the current study. These included 79 patients with PT and 33 subjects defined as healthy. The subjects were recruited at the Department of Periodontics of Pusan National University Dental Hospital, Yangsan, South Korea. In general, we enrolled individuals who were not pregnant or breastfeeding, had no systemic diseases that may affect the periodontal status, and had not received antibiotics in the last 6 months or undergone periodontal therapy (scaling and root planning) in the last 3 months. Exclusion criteria included the use of anti-inflammatory drugs, acute infection (e.g. herpetic gingivostomatitis), chronic mucosal lesion (e.g. pemphigus and pemphigoid) of the oral cavity, and a current status of smoking.

Full-mouth clinical examinations, including probing depth (PD), clinical attachment level (CAL), gingival index (GI), and plaque index (PI), were carried out by one practitioner. Patients with PT had moderate-to-severe periodontal disease, including PD > 5 mm, clinical attachment loss > 3 mm, and radiographic evidence of distinct bone loss. The healthy control (H) group consisted of individuals with clinically healthy gingival tissues (low scores of bleeding on probing in <10% of the sites and no sites with PD > 3 mm or CAL). For clinical follow up, the clinical examinations were performed again 3 to 6 months after treatment in the PT group.

The experimental protocol was approved by the Institutional Review Board of Pusan National University (PNUDH-2017-023). Written informed consent was obtained from all participants before the study.

Microbial sample collection

Buccal and supragingival samples were collected with the full-mouth periodontal examination. All participants were requested to refrain from food and oral hygiene (brushing or flossing the teeth) for 2 h before sampling. Samples were collected after isolating the selected sampling site with cotton rolls and gentle air drying. Buccal swab samples were obtained from the mucosa of both the cheeks with a sterile swab and supragingival plaque samples were collected from the molars of each participant using a sterile Gracey curette. Obtained samples were placed in a sterile 1.5 mL microcentrifuge tube and stored at −80°C for subsequent processing.

Saliva sample collection

Whole saliva was obtained from all study subjects using Salivette (Sarstedt, Numbrecht, Germany). Following plaque sampling, all subjects were asked to rinse their mouth with distilled water 5 min prior to saliva collection. At the time of saliva collection, each subject placed a cotton ball in their mouth for 5 min. The cotton ball was removed and transferred to a plastic tube. Collected samples were centrifuged and the saliva was stored at −80°C until further analysis.

16S rRNA metagenomic sequencing and microbiome analysis

DNA from plaque samples was extracted using the MasterPure Gram Positive DNA purification kit (Lucigen, Middleton, WI) according to the manufacturer’s protocol. The final concentration was measured with a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA) and stored at −80°C until use. The 16S rRNA genes were amplified from input genomic DNA using 16S V3-V4 primers. The sequencing library was prepared according to the 16S Metagenomic Sequencing Library protocols (Illumina, San Diego, CA). The quality and quantity of the DNA sequencing library were assessed using the PicoGreen assay kit (Molecular Probes, Eugene, OR). The libraries were sequenced using MiSeq platforms (Illumina). Basic microbiome analyses have been previously performed using the QIIME2 [18] and associated plugins.
1H nuclear magnetic resonance (NMR) spectral acquisition and analysis of saliva samples

For the NMR measurement, saliva samples of the H group and PT patients were thawed at 4°C and centrifuged at 10,000 rpm for 1 min. The supernatant (450 μL) was collected and mixed with 50 μL of phosphate buffer (pH 7.4) in deuterated water containing 20 mM 3-trimethylsilyl-2,2,3,3-tetradeuteropropionicacid-d$_4$ (TSP-d$_4$; Sigma-Aldrich, St. Louis, MO). TSP-d$_4$ was added as the internal standard for chemical shift and quantitative standard. The prepared sample was vortexed and transferred to a 5 mm NMR tube.

1H-NMR spectra were acquired using a 600 MHz NMR spectrometer with a liquid probe (Agilent Technologies, Santa Clara, CA) operating at 25°C. A Carr-Purcell-Meiboom-Gill pulse sequence was used to suppress the water and macromolecular signals with the following acquisition parameters: spectral width 9615.4 Hz, 3 s acquisition time, and 128 scans. The baseline and phase correction of the acquired spectra were manually processed; the TSP-d$_4$ peak was referenced as 0 ppm with VnmrJ 4.2 software (Agilent Technologies). The spectral region between 0.5 and 10.0 ppm was binned into regions of 0.05 ppm width, omitting the areas of water (from 4.68 to 4.88 ppm). The binned data were normalized, and the multivariate pattern recognition analysis was performed using SIMCA P+ (Umetrics, Umeå, Sweden).

Metabolites were identified and quantified with the Chenomx software 7.1 (Chenomx Inc., Edmonton, AB, Canada) based on the 600 MHz NMR library. The metabolite concentrations were normalized by the sum to reduce sample variation. To confirm the significant metabolites between the H group and PT patients, statistical analysis was performed with Student’s t-test and ANOVA.

Bioinformatics analysis, statistical analyses, and visualization

The mean clinical parameters were compared using the paired Student’s t-test or ANOVA test. NMR data were converted from NMR Suite professional software format (Chenomx Inc.) to Excel format (*csv) (Microsoft Corporation, Redmond, WA) for analysis. Orthogonal partial least squares to latent structures discriminant analysis (OPLS-DA) score plot of 1H NMR spectra was conducted using R to reveal the difference in metabolic patterns between the H and PT groups. Alpha diversity of the sample microbiota was estimated using the Shannon index. The Mann–Whitney U-test was used to compare significant differences of the alpha diversity indices between the different groups. To evaluate the similarity of microbial community structure among all samples, a principal coordinate analysis (PCoA) was performed. Analysis of similarities was calculated to compare the intra- and inter-group similarities based on the Bray Curtis distance, which was calculated by QIIME. A pre-trained Naive Bayes classifier, linked to the Human Oral Microbiome Database (eHOMD) 16S rRNA Extended RefSeq sequences (version 15.1) [19], was used to assign taxonomy to the unique representative sequences. Taxa that were significantly different among groups were identified by linear discriminant analysis effect size (LEfSe) with default settings [20]. Correlations between the relative abundance of microbes and metabolites were analyzed by sparse partial least squares (sPLS) regression analysis using the mixOmics package for R [21]. Within-group differences between pretreatment and follow-up were detected with the Wilcoxon test. Between-group differences were assessed with the Mann–Whitney test. Differences were considered significant at p < 0.05. All data were analyzed using Graph Pad Prism 7 software (GraphPad Software, Inc., San Diego, CA), R version 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria), Cytoscape [22], and Excel (Microsoft Corporation).

Data availability

The raw sequencing data have been deposited at NCBI GenBank under BioProject ID PRJNA625671 (BioSample SAMN14604593 – SAMN14604814). Please check the data using the below private reviewer link:

https://dataview.ncbi.nlm.nih.gov/object/PRJNA625671?reviewer=srlljq2nla5rfl69rdjgmqfusp

The codes are available at (http://doi.org/10.5281/zenodo.4438035).

Results

Patient characterization and subgrouping in the PT group

The demographic and clinical parameters of the participants are detailed in Table 1. PD, CAL, GI, and PI values were significantly higher in the PT group than in the H group. Based on metabolome clustering, the PT group was divided into two subgroups: PT_G1 and PT_G2. The PT_G2 subgroup had a significantly higher percentage of male patients and higher PI value than the PT_G1 subgroup.

NMR analysis of saliva

A total of 28 metabolites was assigned in saliva. This was consistent with the findings of previous studies on saliva metabolites [23,24]. The normalized
### Table 1. Epidemiologic characterization of patients.

| Group                          | Healthy (n = 32) | Total CP (n = 79) | PT_G1 (n = 41) | PT_G2 (n = 38) | H vs total CP | H vs PT_G1 | H vs PT_G2 | PT_G1 vs PT_G2 |
|-------------------------------|------------------|-------------------|----------------|----------------|---------------|------------|------------|----------------|
| Age (mean ± SD)               | 30.03 ± 7.19     | 53.99 ± 9.55      | 52.66 ± 8.49   | 54.26 ± 10.42  | ***           | ***        | ***        | -              |
| Gender (Male/Female)          | 15/18            | 48/31             | 19/22          | 29/9           | -             | -          | -          | **             |
| Periodontitis Severity (Moderate/Severe) | -               | 46/33             | 26/15          | 20/18          | -             | -          | -          | -              |
| PD (mean ± SD)                | 2.31 ± 0.29      | 3.52 ± 0.74       | 3.45 ± 0.81    | 3.60 ± 0.65    | ***           | ***        | ***        | -              |
| C1 (mean ± SD)                | 2.31 ± 0.29      | 3.91 ± 0.93       | 3.84 ± 0.89    | 3.99 ± 0.98    | ***           | ***        | ***        | ***            |
| GI (mean ± SD)                | 0.12 ± 0.14      | 0.99 ± 0.49       | 0.99 ± 0.55    | 0.99 ± 0.45    | ***           | ***        | ***        | ***            |
| PI % (mean ± SD)              | 19.96 ± 21.62    | 59.47 ± 25.67     | 53.65 ± 26.05  | 63.39 ± 24.10  | ***           | ***        | ***        | ***            |

*p < 0.05, **p < 0.01, ***p < 0.001.
concentration of metabolites, including their average concentrations and standard deviation, is provided in Table S1. The OPLS-DA plot distinguished the H group from the PT group based on metabolite profiles (Figure 1(a)). While the H group metabolite profiles were scattered, suggesting heterogeneous composition, the metabolite profiles of the PT patients were clustered. When OPLS-DA was applied to the PT group, two clusters were found. Thus, the PT group was clustered into the PT_G1 and PT_G2 subgroups (Figure 1(b)) for further analyses.

To confirm the metabolic differences, Variable Importance in Projection (VIP) scores of the important discriminatory metabolites were obtained from the OPLS-DA models (Figure 1(c)). Compared with the H group, the butyrate and choline levels significantly increased in the PT_G1 patients. In the PT_G2 patients, the acetate, butyrate, choline, and propionate levels were significantly increased compared to those in the H group. The PT_G2 patients also showed higher concentration of acetate and propionate than PT_G1 patients (Figure 1(d)).

Microbiome diversity and abundance

To characterize the microbiota composition, 16S rRNA V3-V4 targeted sequencing was performed. The diversity of the microbiota was estimated using the Shannon index (Figure 2(a)). Although not statistically significant, the Shannon index values for buccal and supragingival plaque samples were higher in the PT group than in the H group (Figure 2(a)). The PT_G2 patients displayed significantly higher diversity in supragingival plaque samples than the H and PT_G1 patients (p < 0.005). To analyze the distribution of microbiota, PCoA was conducted. This analysis revealed a pattern of clustering depending on the source groups of the buccal samples (Figure 2(b)). The PT_G2 and H buccal samples clustered together and could not be distinguished from each other, while the PT_G1 buccal samples clustered apart. Supragingival plaque samples were more dispersive, and the associated groups could not be distinguished from each other (Figure 2(b)). Thus, we could not find any distinctive feature in the diversity analysis.

Next, we analyzed the overall abundance at the phylum and genus levels. In buccal samples, the five most abundant phyla were Firmicutes, Proteobacteria, Bacteroidetes, Actinobacteria, and Fusobacteria, which represented more than 95% of the total phyla. In samples of supragingival plaque, the aforementioned five phyla also constituted the majority. In PT patients, the abundance of spirochetes was increased in both buccal and supragingival plaque samples (Figure 2(c)). At the genus level, among the 195 genera detected, the most abundant in buccal samples were Streptococcus, Haemophilus, Rothia, Neisseria, Capnocytophaga, Lautropia, Fusobacterium, Veillonella, and Prevotella. These constituted more than 75% of the total genera. In supragingival plaque samples, Streptococcus, Haemophilus, Rothia, Neisseria,
Prevotella, Fusobacterium, Actinomyces, Capnocytophaga, Veillonella, and Leptotrichia represented more than 70% of the total genera (Figure 2(d)).

Comparison of species taxa

Next, the LEfSe algorithm [20] was used to determine discriminant bacterial species. In buccal samples, among the most significant taxa, Gemella haemolysans, P. gingivalis, Filifactor alocis, Fusobacterium nucleatum, and T. forsythia were more abundant in the PT group than in the H group. The abundance of Haemophilus parainfluenzae, Prevotella melaninogenica, and Corynebacterium pseudotuberculosis was significantly higher in the H group than in the PT group (Figure 3(a,b)). When the PT_G1 and PT_G2 subgroups were compared, significant taxa, including T. denticola and Treponema socranski, were more abundant in the PT_G2 subgroup (Figure 3(c)). Concerning supragingival plaque samples, Streptococcus sanguinis, Capnocytophaga species (including C. granulosa, C. sputigena, and C. leadbetteri), P. gingivalis, F. alocis, and T. socranski were significantly more abundant in the PT group than in the H group. In the H group, the abundance of H. parainfluenzae, Rothia dentocariosa, Actinomyces johnsonii, and Kingella oralis was significantly higher than that in the PT group (Figure 3(d,e)). When the PT_G1 and PT_G2 subgroups were compared, the abundance of T. forsythia and Prevotella species that included P. salivae, P. ulcerum, P. saccharolytica, and P. loescheii was significantly higher in the PT_G2 subgroup (Figure 3(f)). The relative abundance of the significant taxa determined by LEfSe was also plotted (Supplementary Figure S1).

Integrated microbiome-metabolome network analysis

To study the correlation between microbiome and metabolome, sPLS regression correlation analysis was performed using mixOmics. For visualization, bacterial species that correlated with short-chain fatty acids (SCFAs), whose concentrations were increased in the PT group, were selected as the first metabolite group. Bacterial species that were connected to the first metabolite group were considered the first microbial group. Metabolites whose concentrations decreased in the PT group were grouped as the second metabolite cluster. Bacterial species that correlated with only the second
metabolite cluster were considered the second bacterial group. In the H and PT_G1 network, acetone, histidine, and lysine, whose concentrations were significantly decreased in the PT_G1 subgroup, showed comparable positive correlations with various bacterial species whose abundance was significantly decreased in the PT_G1 subgroup. These species included Streptococcus salivar-sius, Prevotella. pallens, Prevotella histicola, P. salivae, Prevotella nanceiensis, and P. melaninogenica. Among the bacterial species with increased abundance in the PT_G1 subgroup, only F. alocis abundance correlated with the butyrate and choline concentrations (Figure 4 (a)). In the H and PT_G2 network, the concentrations of SCFAs, which included acetone, butyrate, choline, and propionate, displayed comparable correlations with bacterial species whose abundance was significantly increased in the PT_G2 subgroup. These species included T. denticola, T. socraskii, F. alocis, T. forsythia, P. gingivalis, Porphyromonas endodontalis, Prevotella dentalis, and F. nucleatum. Interestingly, the acetate concentration was correlated with the abundance of most bacteria, while the butyrate and choline concentrations showed a similar range of correlation with the abundance of classically classified periodontopathogens, including T. denticola, F. alocis, T. socraskii, F. nucleatum, T. forsythia, and P. gingivalis. The propionate concentration was correlated only with T. denticola and F. alocis abundance (Figure 4(b)).

Clinical follow-up

In the follow-up, the PT_G1 and PT_G2 subgroups both displayed improved PD; no statistically significant differences were observed between the two groups at 3 to 6 months (p > 0.05, Table 2). In the PT_G1 subgroup, GI was also significantly improved, while PI was significantly improved in the PT_G2 subgroup. Between baseline and follow-up, PD reduction was 0.79 ± 0.058 mm and 1.26 ± 0.53 mm in the PT_G1 and PT_G2 subgroups, respectively. The reduction in CAL was 0.64 ± 0.83 mm and 0.87 ± 0.88 mm in the two subgroups, respectively. These differences were not statistically significant between the groups.
Discussion

PT is the most prevalent type of periodontal disease. It affects approximately 70% of people aged 65 years and older. If untreated, PT leads to tooth loss. The risk of PT increases with age and is closely associated with systemic diseases, such as cardiovascular disease, diabetes, rheumatoid arthritis, and Alzheimer’s disease [25,26]. Therefore, early diagnosis of PT is important for both a healthy mouth and general health. However, currently, the diagnosis of PT is entirely based on clinical inspection and radiographic parameters [1,2]. Despite the knowledge that PT is
a multifactorial chronic inflammatory disease caused by the interaction between oral pathogens and host tissues, no microbiological evaluation or assessment method for metabolites produced by periodontal pathogens is available for diagnosing this disease.

In this study, we applied multi-omics analysis of PT that combined microbiome analysis and metabolome analysis. Compared to single omics, multi-omics data analysis can provide researchers with a greater understanding of the disease [27,28]. First, we compared the metabolite profile of saliva samples collected from the H group with that of the samples collected from the PT group. While metabolite profiles of the H group were scattered, which suggest a heterogeneous composition, those from the PT group were more well clustered (Figure 1(a)). Among the metabolites identified, the butyrate and choline concentrations were significantly increased in the PT group compared to the H group. Butyrate has been suggested to contribute to the progression of periodontal disease [29–31]. The elevated concentrations of butyrate and propionate have been reported in gingival crevicular fluid collected from aggressive PT patients [32]. Thus, our findings are largely comparable to those of previous studies.

In the buccal microbiome analysis, P. gingivalis, F. alocis, F. nucleatum, and T. forsythia were among the significant species that were more abundant in the PT group (Figure 3(a,b)). In supragingival plaque samples, Capnocytophaga species, Eikenella corrodens, P. gingivalis, F. alocis, and T. socranskii were significantly more prevalent in the PT group (Figure 3(d,e)). Overall, our findings from the single microbiome analysis were largely comparable to those of previous studies [10,33–35].

Metabolites found in the saliva may originate from the microbiome on mucous membranes, such as the buccal mucosa or accumulated plaque. In single omics studies, since other parameters are not available, subgrouping is not commonly performed. Presently, we could cluster the PT patients depending on metabolite profiles and further characterize their microbiome composition. In the PT_G2 subgroup, which had a significantly higher concentration of short-chain fatty acids (including butyrate, acetate, choline and propionate), Eubacterium nodatum, Dialister pneumosintes, Mogibacterium timidum, P. endodontalis, P. dentalis, T. denticola, and T. socranskii were significantly more prevalent in buccal samples. In supragingival plaque samples collected from the PT_G2 group, the abundance of Freitibacterium fastidiosum, Leptotrichia buccalis, M. timidum, Parvinoma micra, Peptostreptococcus stomatis, Selenomonas noxia, T. forsythia, and T. denticola were significantly increased compared to that in the H group.

‘Refractory periodontitis’ was historically referred to as destructive periodontal diseases in patients who, when longitudinally monitored, demonstrated additional attachment loss at one or more sites, despite well-executed periodontal treatment and patient efforts to stop the progression of disease [36]. In 1993, the categories of PT associated with systemic disease and refractory PT were dropped from the classification [37]. As a consequence, only a limited number of studies have attempted to characterize the microbiome in ‘refractory’ PT. Interestingly, many bacteria that were more abundant in the PT_G2 subgroup were also in the list of bacteria found more commonly in ‘refractory’ PT than in general PT or healthy subjects. Bacterial species that include P. micra, T. forsythia, Prevotella spp., P. gingivalis, E. nodatum, Eubacterium spp., Selenomonas spp., and Treponema spp. are reportedly more prevalent in ‘refractory’ PT than in general PT or the healthy state [38,39]. In more recent studies that utilized microarray analysis, subjects with ‘refractory’ PT displayed significantly higher frequencies of P. gingivalis, P. endodontalis, F. alocis, E. corrodens, Eubacterium spp. E. nodatum, Selenomonas spp., S. noxia, T. forsythia, Prevotella spp., Treponema spp., Dialister invisus/pneumosintes, M. timidum, Peptostreptococcus spp., and P. micra [11,40]. From a clinical perspective, we observed a significantly higher percentage of male patients in the PT_G2 subgroup. These patients displayed a higher PI than the PT_G1 subgroup (Table 1). The collective findings indicated that the oral microbiome of PT_G2 patients showed similar features to refractory PT patients who had responded poorly to conventional therapy in the past.

To study the interplay between microbiome and metabolome, a correlation analysis was performed using mixOmic [21]. In the H and PT_G2 network,
the abundance of numerous periodontopathogens was positively correlated with the SCFA concentrations. Butyrate and choline showed a correlation with the classical periodontopathogens including *T. denticola*, *F. alocis*, *T. socraskii*, *F. nucleatum*, *T. forsythia*, and *P. gingivalis*. Butyrate and acetate are the major by-products of anaerobic metabolism in periodontopathogens, such as *Porphyromonas*, *Prevotella*, and *Fusobacterium* species [12,41]. In *vitro* culture studies have demonstrated that *P. gingivalis* and *F. nucleatum* produce more amounts of butyrate and acetate [31,42]. In gingival crevicular fluids obtained from patients with aggressive PT, the concentrations of acetic, propionic, and butyric acids were positively correlated with *P. gingivalis* and *T. denticola* abundance [43]. Thus, our network analysis was comparable to previous studies.

To determine the clinical outcome in the PT_G1 and PT_G2 subgroups, clinical parameters were checked in a follow-up visit, 3 to 6 months after periodontal treatment. Although there were no statistically significant differences, the PT_G2 group showed higher PD and CAL change. Considering the microbiome and its related metabolic profile, long-term follow-up should be performed to evaluate the clinical outcome.

In summary, we successfully integrated multi-omics data and identified a subgroup of periodontitis patients based on metabolomic and microbiome features. The strength of our study is that the use of the multi-omics approach provided rich and complementary understanding into the analysis of periodontitis compared to single-omics studies. Especially, interaction between the metabolites in the saliva and the related microbiomes in buccal sites support previous *in vivo* and *in vitro* studies [12,31,41,42]. Our study also shows the potential of multi-omics approach in predicting PT treatment outcome at the molecular level.

There are several limitations in this study. Our study uses a relatively small sample size suggesting that these findings should be validated in a larger clinical cohort. An adequate number of participants would be needed to allow stratification of participants into different sexes, clinical stage, or lifestyle. The lack of this stratification may influence the results of this study and should be evaluated in the future. Also, long-term clinical follow-up could be valuable. The findings open new avenues to explore the oral microbiome-metabolome associations for biomarker discovery for the diagnosis and management of PT.

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**Funding**

This research was supported by the National Research Foundation of Korea (NRF) funded by the Ministry of Science & ICT [NRF-2017M3A9B6062027].

**References**

[1] Tonetti MS, Greenwell H, Kornman KS. Staging and grading of periodontitis: framework and proposal of a new classification and case definition. J Periodontol. 2018;89(Suppl 1):S159–S72. Epub 2018/06/22. PubMed PMID: 29926952.

[2] Staderini E, Guglielmi F, Cornelis MA, et al. Three-dimensional prediction of roots position through cone-beam computed tomography scans-digital model superimposition: a novel method. Orthod Craniofac Res. 2019;22(1):16–23. PubMed PMID: 30449070.

[3] Jannes G, De Vos D. A review of current and future molecular diagnostic tests for use in the microbiology laboratory. Methods Mol Biol. 2006;345:1–21. Epub 2006/09/08. PubMed PMID: 16957343.

[4] Forbes JD, Knox NC, Ronholm J, et al. Metagenomics: the next culture-independent game changer. Front Microbiol. 2017;8:1069. Epub 2017/07/21. PubMed PMID: 28725217; PMCID: PMC5495826.

[5] Petsosino JF. The microbiome in precision medicine: the way forward. Genome Med. 2018;10(1):12. Epub 2018/02/24. PubMed PMID: 29471863; PMCID: PMC5824491.

[6] Socransky SS, Haffajee AD. Periodontal microbial ecology. Periodontol 2000. 2005;38:135–187. Epub 2005/04/28. PubMed PMID: 15853940.

[7] Slots J, Genco RJ. Black-pigmented bacteroides species, Capnocytophaga species, and actinobacillus actinomycetemcomitans in human periodontal disease: virulence factors in colonization, survival, and tissue destruction. J Dent Res. 1984;63(3):412–421. Epub 1984/03/01. PubMed PMID: 6583243.

[8] Kolenbrander PE, Andersen RN, Moore LV. Coaggregation of Fusobacterium nucleatum, Selenomonas flueggei, Selenomonas infelix, Selenomonas noxia, and Selenomonas spuitgena with strains from 11 genera of oral bacteria. Infect Immun. 1989;57(10):3194–3203. PubMed PMID: 2777378; PMCID: PMC260789.

[9] Hill GB, Ayers OM, Kohan AP. Characteristics and sites of infection of Euubacterium nodatum, Euabacterium timidium, Euabacterium brachy, and other asaccharolytic eubacteria. J Clin Microbiol. 1987;25(8):1540–1545. Epub 1987/08/01. PubMed PMID: 3624445; PMCID: PMC269265.

[10] Kumar PS, Griffen AL, Moeschberger ML, et al. Identification of candidate periodontal pathogens and beneficial species by quantitative 16S clonal analysis. J Clin Microbiol. 2005;43(8):3944–3955. Epub 2005/08/06. PubMed PMID: 16081935; PMCID: PMC1233920.

[11] Colombo AP, Boches SK, Cotton SL, et al. Comparisons of subgingival microbial profiles of refractory periodontitis, severe periodontitis, and periodontal health using the human oral microbe identification microarray. J Periodontol. 2009;80(9):1421–1432. Epub 2009/09/03. PubMed PMID: 19722792; PMCID: PMC3627366.
[12] Singer RE, Buckner BA. Butyrate and propionate: important components of toxic dental plaque extracts. Infect Immun. 1981;32(2):458–463. Epub 1981/05/09. PubMed PMID: 7251132; PMCID: PMC351466.

[13] Shirasugi M, Nakagawa M, Nishioka K, et al. Relationship between periodontal disease and butyric acid produced by periodontopathic bacteria. Inflamm Regen. 2018;38:23. Epub 2018/12/24. PubMed PMID: 30574217; PMCID: PMC6296098.

[14] Califf KJ, Schwarzberg-Lipson K, Garg N, et al. Multi-omics analysis of periodontal pocket microbial communities pre- and posttreatment. mSystems. 2017;2(3). PubMed PMID: 28744486. DOI:10.1128/mSystems.00016-17.

[15] German JB, Hammock BD, Watkins SM. Metabolomics: building on a century of biochemistry to guide human health. Metabolomics. 2005;1(1):3–9. Epub 2006/05/09. PubMed PMID: 16680201; PMCID: PMC1457093.

[16] Keun HC, Ebbels TM, Antti H, et al. Analytical reproducibility in (1)H NMR-based metabolomic urine analysis. Chem Res Toxicol. 2002;15(11):1380–1386. Epub 2002/11/20. PubMed PMID: 12437328.

[17] Nicholson JK, Lindon JC. Systems biology: metabolomics. England: Nature; 2008. p. 1054–1056.

[18] Bolyen E, Rideout JR, Dillon MR, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2 (vol 37, pg 852, 2019). Nat Biotechnol. 2019;37(9):1091. PubMed PMID: WOS:000488532000025.

[19] Wade WG. The oral microbiome in health and disease. Pharmacol Res. 2013;69(1):137–143. Epub 2012/12/04. PubMed PMID: 23201354.

[20] Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12(6):R60. Epub 2011/06/28. PubMed PMID: 21702898; PMCID: PMC3218848.

[21] Rohart F, Gautier B, Singh A, et al. mixOmics: an R package for ‘omics feature selection and multiple data integration. PLoS Comput Biol. 2017;13(11):e1005752. Epub 2017/11/04. PubMed PMID: 29099853; PMCID: PMC5687754.

[22] Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of molecular interaction networks. Genome Res. 2003;13(11):2498–2504. Epub 2003/11/05. PubMed PMID: 14597658; PMCID: PMC403769.

[23] Mikkonen JJ, Singh SP, Herrala M, et al. Salivary metabolomics in the diagnosis of oral cancer and periodontal diseases. J Periodontal Res. 2016;51(4):431–437. Epub 2015/10/09. PubMed PMID: 26446036.

[24] Romano F, Meoni G, Manavella V, et al. Analysis of salivary phenotypes of generalized aggressive and chronic periodontitis through nuclear magnetic resonance-based metabolomics. J Periodontol. 2018;89(12):1452–1460. Epub 2018/06/08. PubMed PMID: 29877582.

[25] Cardoso EM, Reis C, Manzanares-Céspedes MC. Chronic periodontitis, inflammatory cytokines, and interrelationship with other chronic diseases. Postgrad Med. 2018;130(1):98–104. Epub 2017/11/08. PubMed PMID: 29065749.

[26] Chen CK, Wu YT, Chang YC. Association between chronic periodontitis and the risk of Alzheimer’s disease: a retrospective, population-based, matched-cohort study. Alzheimers Res Ther. 2017;9(1):56. Epub 2017/08/09. PubMed PMID: 28784164; PMCID: PMC5547465.

[27] Civelek M, Lusis AJ. Systems genetics approaches to understand complex traits. Nat Rev Genet. 2014;15(1):34–48. Epub 2013/12/04. PubMed PMID: 24296534; PMCID: PMC3934510.

[28] Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18(1):83. Epub 2017/05/10. PubMed PMID: 28476144; PMCID: PMC5418815.

[29] Chang MC, Tsai YL, Chen YW, et al. Butyrate induces reactive oxygen species production and affects cell cycle progression in human gingival fibroblasts. J Periodontol Res. 2013;48(1):66–73. Epub 2012/07/28. PubMed PMID: 22834967.

[30] Jeng JH, Chan CP, Ho YS, et al. Effects of butyrate and propionate on the adhesion, growth, cell cycle kinetics, and protein synthesis of cultured human gingival fibroblasts. J Periodontol. 1999;70(12):1435–1442. Epub 2000/01/13. PubMed PMID: 10652518.

[31] Kurita-Ochiai T, Seto S, Suzuki N, et al. Butyric acid induces apoptosis in inflamed fibroblasts. J Dent Res. 2008;87(1):51–55. Epub 2007/12/22. PubMed PMID: 18096893.

[32] Lu RF, Meng HX, Gao XJ, et al. [Analysis of short chain fatty acids in gingival crevicular fluid of patients with aggressive periodontitis]. Zhonghua Kou Qiang Yi Xue Za Zhi. 2008;43(11):664–667. Epub 2008/12/18. PubMed PMID: 19087639.

[33] Belda-Ferre P, Alcaraz LD, Cabrera-Rubio R, et al. The oral metagenome in health and disease. Isme J. 2012;6(1):46–56. Epub 2011/07/01. PubMed PMID: 21716308; PMCID: PMC3246241.

[34] Junemann S, Prior K, Szczepanowski R, et al. Bacterial community shift in treated periodontitis patients revealed by ion torrent 16S rRNA gene amplicon sequencing. PLoS One. 2012;7(8):e41606. Epub 2012/08/08. PubMed PMID: 22870235; PMCID: PMC3411582.

[35] Griffen AL, Bell CJ, Campbell JH, et al. Distinct and complex bacterial profiles in human periodontitis and health revealed by 16S pyrosequencing. Isme J. 2012;6(6):1176–1185. Epub 2011/12/16. PubMed PMID: 22170420; PMCID: PMC3358035.

[36] Parameter on “refractory” periodontitis. J Periodontol. 2000;71(Suppl 5S):859–860. Epub 2000/05/01. PubMed PMID: 29537510.

[37] Armitage GC. Development of a classification system for periodontal diseases and conditions. Annals of Periodontology. 1999;4(1):1–6. Epub 2000/06/23. PubMed PMID: 10863370.

[38] Haffajee AD, Socransky SS, Dzink JL, et al. Clinical, microbiological and immunological features of subjects with refractory periodontal diseases. J Clin Periodontol. 1988;15(6):390–398. Epub 1988/07/01. PubMed PMID: 3165398.

[39] Listgarten MA, Lai CH, Young V. Microbial composition and pattern of antibiotic resistance in subgingival microbial samples from patients with refractory periodontitis. J Periodontol. 1993;64(3):155–161. Epub 1993/03/01. PubMed PMID: 8463936.

[40] Colombo AP, Bennet S, Cotton SL, et al. Impact of periodontal therapy on the subgingival microbiota of severe periodontitis: comparison between good responders and individuals with refractory periodontitis using the human oral microbe identification
microarray. J Periodontol. 2012;83(10):1279–1287. Epub 2012/02/14. PubMed PMID: 22324467; PMCID: PMC3971922.

[41] Eftimiadi C, Tonetti M, Cavallero A, et al. Short-chain fatty acids produced by anaerobic bacteria inhibit phagocytosis by human lung phagocytes. J Infect Dis. 1990;161(1):138–142. Epub 1990/01/01. PubMed PMID: 2295846.

[42] Yu X, Shahir AM, Sha J, et al. Short-chain fatty acids from periodontal pathogens suppress histone deacetylases, EZH2, and SUV39H1 to promote Kaposi’s sarcoma-associated herpesvirus replication. J Virol. 2014;88(8):4466–4479. Epub 2014/02/07. PubMed PMID: 24501407; PMCID: PMC3993761.

[43] Lu RF, Feng L, Gao XJ, et al. [Relationship between volatile fatty acids and Porphyromonas gingivalis and Treponema denticola in gingival crevicular fluids of patients with aggressive periodontitis]. Beijing Da Xue Xue Bao Yi Xue Ban. 2013;45(1):12–16. Epub 2013/02/16. PubMed PMID: 23411512.